Pantoprazole, a proton pump inhibitor, delays fracture healing in mice

Calcified Tissue International

Volumn 90, Issue 6, 2012, Pages 507-514

  Histing, T ^a,b   Stenger, D ^a,b   Scheuer, C ^a,b   Metzger, W ^a,b   Garcia, P ^a,b   Holstein, J H ^a,b   Klein, M ^a,b   Pohlemann, T ^a,b   Menger, M D ^a,b  

^a SAARLAND UNIVERSITY   (Germany)

^b AO FOUNDATION   (Switzerland)

Author keywords

Bone formation marker; Bone healing; Bone remodeling; Fracture repair; RANKL

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CELL NUCLEUS ANTIGEN; CYSTEINE RICH PROTEIN 61; OSTEOCLAST DIFFERENTIATION FACTOR; PANTOPRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BIOMECHANICS; BONE TISSUE; CALLUS; CELL PROLIFERATION; CONTROLLED STUDY; FRACTURE HEALING; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIGIDITY; WESTERN BLOTTING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONY CALLUS; CYSTEINE-RICH PROTEIN 61; FRACTURE HEALING; MALE; MICE; MICE, INBRED C57BL; PROTON PUMP INHIBITORS; RANK LIGAND;

EID: 84864277925     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-012-9601-x     Document Type: Article

References (33)

1. Ferron GM, McKeand W, Mayer PR (2001) Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. J Clin Pharmacol 41:149-156 (Pubitemid 32106052)
2. Lindberg P, Nordberg P, Alminger T et al (1986) The mechanism of action of the gastric acid secretion inhibitor omeprazole. J Med Chem 29:1327-1329 (Pubitemid 16034616)
3. Graziani G, Como G, Badalamenti S et al (1995) Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant 10:1376-1380
4. O'Connell MB, Madden DM, Murray AM et al (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778-781 (Pubitemid 40897665)
5. Targownik LE, Lix LM, Metge CJ et al (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179:319-326
6. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947-2953 (Pubitemid 46021498)
7. Yu EW, Blackwell T, Ensrud KE et al (2008) Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 83:251-259
8. Tucker KL, Hannan MT, Qiao N et al (2005) Low plasma vitamin B12 is associated with lower BMD: the Framingham Osteoporosis Study. J Bone Miner Res 20:152-158 (Pubitemid 41716230)
9. Farina C, Gagliardi S (2002) Selective inhibition of osteoclast vacuolar H?-ATPase. Curr Pharm Des 8:2033-2048 (Pubitemid 34982169)
10. Tuukkanen J, Väänänen HK (1986) Omeprazole, a specific inhibitor of H?-K?-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int 38:123-125 (Pubitemid 16113857)
11. Mizunashi K, Furukawa Y, Katano K, Abe K (1993) Effect of omeprazole, an inhibitor of H?,K?-ATPase, on bone resorption in humans. Calcif Tissue Int 53:21-25 (Pubitemid 23187327)
12. Visentin L, Dodds RA, Valente M et al (2000) A selective inhibitor of the osteoclastic V-H?-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J Clin Invest 106:309-318 (Pubitemid 30483135)
13. Bilic I, Zoricic I, Anic T et al (2001) Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice. Life Sci 68: 1905-1912 (Pubitemid 32245614)
14. Masubuchi N, Hakusui H, Okazaki O (1997) Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors. Drug Metab Dispos 25:584-589 (Pubitemid 27213099)
15. Holstein JH, Matthys R, Histing T et al (2008) Development of a stable closed femoral fracture model in mice. J Surg Res 153: 71-75
16. Goldberg VM, Powell A, Shaffer JW et al (1985) Bone grafting: role of histocompatibility in transplantation. J Orthop Res 3:389-404 (Pubitemid 16205185)
17. Histing T, Holstein JH, Garcia P et al (2009) Ex vivo analysis of rotational stiffness of different osteosynthesis techniques in mouse femur fracture. J Orthop Res 27:1152-1156
18. Gerstenfeld LC, Wronski TJ, Hollinger JO, Einhorn TA (2005) Application of histomorphometric methods to the study of bone repair. J Bone Miner Res 20:1715-1722 (Pubitemid 41361872)
19. Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123: 877-884
20. Zaidi M (1990) Modularity of osteoclast behaviour and''modespecific'' inhibition of osteoclast function. Biosci Rep 10: 547-556
21. Sheraly AR, Lickorish D, Sarraf F, Davies JE (2009) Use of gastrointestinal proton pump inhibitors to regulate osteoclastmediated resorption of calcium phosphate cements in vivo. Curr Drug Deliv 6:192-198
22. Karsdal MA, Henriksen K, Sørensen MG et al (2005) Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166:467-476 (Pubitemid 40189043)
23. Hyun JJ, Chun HJ, Keum B et al (2010) Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts. Int J Mol Med 26:877-883
24. Gerstenfeld LC, Sacks DJ, Pelis M et al (2009) Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 24:196-208
25. Marsell R, Einhorn TA (2009) The role of endogenous bone morphogenetic proteins in normal skeletal repair. Injury 40:4-7
26. Tsuji K, Bandyopadhyay A, Harfe BD et al (2006) BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 38:1424-1429 (Pubitemid 44837565)
27. Devlin RD, Du Z, Pereira RC et al (2003) Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 144:1972-1978 (Pubitemid 36543336)
28. Schütze N, Lechner A, Groll C et al (1998) The human analog of murine cystein rich protein 61 is a 1alpha,25-dihydroxyvitamin D3 responsive immediate early gene in human fetal osteoblasts: regulation by cytokines, growth factors, and serum. Endocrinology 139:1761-1770 (Pubitemid 28513835)
29. Si W, Kang Q, Luu HH et al (2006) CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3Ainduced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol 26:2955-2964
30. Su JL, Chiou J, Tang CH et al (2010) CYR61 regulates BMP- 2-dependent osteoblast differentiation through the avb3 integrin/integrin- linked kinase/ERK pathway. J Biol Chem 285:31325-31336
31. Hadjiargyrou M, Ahrens W, RubinCT(2000) Temporal expression of the chondrogenic and angiogenic growth factor CYR61 during fracture repair. J Bone Miner Res 15:1014-1023 (Pubitemid 30350064)
32. Crockett JC, Schütze N, Tosh D et al (2007) The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5. Endocrinology 48:5761-5768
33. Schütze N, Kunzi-Rapp K, Wagemanns R et al (2005) Expression, purification, and functional testing of recombinant CYR61/ CCN1. Protein Expr Purif 42:219-225 (Pubitemid 40793414)